The embodiments described herein generally relate to a hydrogel formulation and to medical supplies including hydrogel formulations such as film dressings, and more particularly IV securement dressings, and wound dressings.
According to an embodiment of the present invention, a transparent film dressing is provided that comprises a transparent film and a hydrogel adhesive formulation coated on one or more sides of the transparent film. The transparent film comprises polyurethane. The hydrogel formulation comprises a medical-grade hydrogel and an antimicrobial substance, wherein the medical-grade hydrogel comprises a colloidal gel in which the particles are dispersed in water. The antimicrobial material is a silane quaternary ammonium salt comprising 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% by weight of the silane quaternary ammonium salt. The hydrogel formulation may include about 0.01% to about 60% by weight of the antimicrobial substance. The transparent film dressing may further comprise a release liner applied over one or more coated sides of the transparent film.
According to another embodiment of the present invention, a hydrogel formulation is provided for use on a film dressing, the hydrogel formulation comprising a medical-grade hydrogel and an antimicrobial substance. The film dressing may be transparent or opaque.
According to another embodiment of the present invention, a transparent film dressing is provided that comprises a transparent film having a hydrogel adhesive formulation coated on one or more sides, where the hydrogel formulation comprises a medical-grade hydrogel and an antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.
In the latter two embodiments, the antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% by weight of the silane quaternary ammonium salt.
Also in these two embodiments, the medical-grade hydrogel may comprise a colloidal gel in which the particles are dispersed in water. Further, the hydrogel formulation may include about 0.01% to about 60% by weight of the antimicrobial substance.
These and other features, advantages, and objects of the present invention will be further understood and appreciated by those skilled in the art by reference to the following specification, claims, and drawings.
In the drawings:
Reference will now be made in detail to the present preferred embodiments of the invention.
A novel hydrogel formulation for film dressings is disclosed herein that not only provides the requisite properties for a hydrogel, but also eliminates bacteria on contact. In general, the hydrogel formulation comprises a hydrogel and an antimicrobial substance, such as a silane quaternary ammonium salt. The hydrogel may be a medical-grade colloidal gel in which the particles are dispersed in water. Preferred commercially available silane quaternary ammonium salts include: MicrobeCare™ XLP, which is available from MicrobeCare, LLC of Allendale, Mich.; “PROMOFRESH X 105” from Piedmont Chemical Industries I, LLC of High Point, N.C.; and AEM 5772 Antimicrobial, which is available from Aegis Environments of Midland, Mich. These particular antimicrobial substances include an active ingredient of about 72% by weight 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride and about 28% by weight inert ingredients. The antimicrobial substance could also be AEGIS Microbe Shield™ (from Aegis Environments, Midland, Mich.), which is a copolymer of chloropropyltrihydroxysilane and octadecylaminodimethyltrihydroxysilylpropyl ammonium chloride.
Silane quaternary ammonium salts are particularly well suited for the antimicrobial material as they are long lasting and capable of emitting ions that aid in the destruction of a microbe. In addition, they are organofunctional silanes that include a monomer including a silane, a positively charged nitrogen molecule, and a long molecular chain. The silane bases of these monomers can covalently and permanently bond to each other and any surface. In addition, silane quaternary ammonium salts are preferable as they are substantially free from arsenic, silver, tin, heavy metals and polychlorinated phenols. Also, they are safe to apply to the skin or to a wound of a patient.
Microbes may include bacteria, mold, mildew, algae, etc. The cell membranes of the microbes are attracted to, and then are punctured by, the long molecular chains of the monomers. As the microbes are drawn closer because of the positive-negative ion exchanges, the monomers penetrate further into the cell membranes. Once the cell membranes are penetrated deeply, they are physically ruptured by a sword-like action and then electrocuted by positively charged nitrogen molecules of the monomers, thus destroying the microbes. Thus, the microbes are eliminated without “using up” any of the antimicrobial active ingredients, which remain in the adhesive formulation ready to continue protecting the patient against further microbial contamination.
The antimicrobial substance may be mixed into the hydrogel in various amounts of anywhere from about 0.01% to about 60% by weight to achieve the desired degree of antimicrobial activity while not compromising the desirable properties of the hydrogel in the resulting mixture.
As shown in the drawings, the hydrogel formulation 2 is coated on one side or both sides of a medical-grade film 1 (i.e., plastic carrier), which may be a transparent film of the type commonly used for wound dressings or securing an intravenous (IV) needle or catheter. One suitable transparent film is a 1-mil polyurethane film available from DermaMed Coatings Company, LLC of Tallmadge, Ohio. The film 1 is preferably oxygen permeable and may have an optional slit 4 for an IV needle or catheter. The coating method may be a knife-over-roll method. According to a first embodiment shown in
The hydrogel-coated transparent film may be used as a wound dressing or for any other medical use such as securing an IV needle to a patient or securing a catheter.
The film may also be opaque and may be of the type that is commonly used for bandages or medical tape.
Modifications of the invention will occur to those skilled in the art and to those who make or use the invention. Therefore, it is understood that the embodiments described above are merely for illustrative purposes and not intended to limit the scope of the invention, which will be defined by claims as interpreted according to the principles of patent law, including the doctrine of equivalents.
This application is a continuation of and claims priority to U.S. patent application Ser. No. 14/049,319, entitled “ANTIMICROBIAL HYDROGEL FORMULATION,” filed on Oct. 9, 2013, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/711,421, entitled “ANTIMICROBIAL HYDROGEL FORMULATION” filed on Oct. 9, 2012, the entire disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4372303 | Grossmann et al. | Feb 1983 | A |
4865844 | Blank et al. | Sep 1989 | A |
4921691 | Stockel | May 1990 | A |
5079004 | Blank et al. | Jan 1992 | A |
5183664 | Ansell | Feb 1993 | A |
5270358 | Asmus | Dec 1993 | A |
5428078 | Cohen et al. | Jun 1995 | A |
5762623 | Murphy et al. | Jun 1998 | A |
5954869 | Elfersy et al. | Sep 1999 | A |
5959014 | Liebeskind et al. | Sep 1999 | A |
6224579 | Modak et al. | May 2001 | B1 |
6495229 | Carte et al. | Dec 2002 | B1 |
6821943 | Avery et al. | Nov 2004 | B2 |
6994890 | Ohlhausen et al. | Feb 2006 | B2 |
7045673 | Batich et al. | May 2006 | B1 |
7704313 | Ohlhausen et al. | Apr 2010 | B2 |
7709694 | Batich et al. | May 2010 | B2 |
7754004 | Ohlhausen et al. | Jul 2010 | B2 |
7790217 | Toreki et al. | Sep 2010 | B2 |
8025120 | Eddy | Sep 2011 | B2 |
8257780 | Ohlhausen et al. | Sep 2012 | B2 |
8440217 | El-Naggar et al. | May 2013 | B1 |
8491922 | Eddy | Jul 2013 | B2 |
8639527 | Rensvold et al. | Jan 2014 | B2 |
8679526 | Van Den Plas et al. | Mar 2014 | B2 |
9028846 | Eddy | May 2015 | B2 |
9433708 | Eddy | Sep 2016 | B2 |
9675735 | Eddy | Jun 2017 | B2 |
9717249 | Eddy | Aug 2017 | B2 |
9877875 | Eddy | Jan 2018 | B2 |
20020111282 | Charaf et al. | Aug 2002 | A1 |
20070021383 | Loder | Jan 2007 | A1 |
20070042198 | Schonemyr et al. | Feb 2007 | A1 |
20070218096 | Wooley | Sep 2007 | A1 |
20080260804 | Morris et al. | Oct 2008 | A1 |
20090215917 | Trotter et al. | Aug 2009 | A1 |
20090223411 | Higgins et al. | Sep 2009 | A1 |
20090252647 | Orofino | Oct 2009 | A1 |
20090312684 | Leonard et al. | Dec 2009 | A1 |
20100028462 | Bolkan et al. | Feb 2010 | A1 |
20100167978 | Iyer et al. | Jul 2010 | A1 |
20100331710 | Eddy | Dec 2010 | A1 |
20110200655 | Black et al. | Aug 2011 | A1 |
20110233810 | Neigel et al. | Sep 2011 | A1 |
20120173274 | Rensvold et al. | Jul 2012 | A1 |
20130101677 | Callahan et al. | Apr 2013 | A1 |
20130231599 | Eddy | Sep 2013 | A1 |
20130345170 | Eddy | Dec 2013 | A1 |
20140100504 | Eddy | Apr 2014 | A1 |
20140271794 | Eddy | Sep 2014 | A1 |
20160143275 | Lan et al. | May 2016 | A1 |
20160143276 | Lan et al. | May 2016 | A1 |
20160262382 | Lan et al. | Sep 2016 | A1 |
20160262383 | Lan et al. | Sep 2016 | A1 |
20170280716 | Lan et al. | Oct 2017 | A1 |
Number | Date | Country |
---|---|---|
0054587 | Sep 2000 | WO |
0072850 | Dec 2000 | WO |
2005042657 | May 2005 | WO |
2007061625 | May 2007 | WO |
2007076413 | Jul 2007 | WO |
2008076839 | Jun 2008 | WO |
2008097599 | Aug 2008 | WO |
2013102021 | Jul 2013 | WO |
Entry |
---|
Rutala et al., “Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008,” Centers for Disease Control (CDC), Department of Health & Human Services, Feb. 15, 2017 (161 pages). |
U.S. Food & Drug Administration (FDA), “Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling Guidance for Industry and Food and Drug Administration Staff,” Mar. 17, 2015 (44 pages). |
European Commission, “Aerosol Dispensers Directive Evaluation—Background document”, Sep. 23, 2016, Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, Belgium (1 page). |
Monticello, Robert A., “The Use of Reactive Silane Chemistries to Provide Durable, Non-Leaching Antimicrobial Surfaces”, AEGIS Environments, Midland, Michigan USA, Jan. 1, 2010 (77 pages). |
AEGIS Environments, Material Safety Data Sheet AEGIS Microbe Shield(TM) Program—AEGIS(TM) Antimicrobial (Typical Application Strength), Midland, Michigan USA, May 12, 2004 (5 pages). |
Anonymous, 2009, SiSiB PC9911 Antimicrobial, Power Chemical Corp, [online]; downloaded from URL<http://www.powerchemcorp.com/library/public/SiSiB_PC9911.pdf> on Oct. 8, 2013; 2 pages. |
Murray et al, “Microbial Inhibition on Hospital Garments Treated with Dow Corning 5700 Antimicrobial Agent,” Journal of Clinical Microbiology, vol. 26, No. 9, Sep. 1988, pp. 1884-1886. |
Number | Date | Country | |
---|---|---|---|
20180092780 A1 | Apr 2018 | US |
Number | Date | Country | |
---|---|---|---|
61711421 | Oct 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14049319 | Oct 2013 | US |
Child | 15819381 | US |